公开(公告)号：US20160016907A1

公开(公告)日：2016-01-21

申请号：US14799621

申请日：2015-07-15

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  JENNIFER ELIZABETH DAVOREN ,  MICHELLE RENEE GARNSEY ,  LEI ZHANG ,  STEVEN VICTOR O'NEIL

IPC: C07D213/81 ,  C07D417/14 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14

CPC classification number: C07D213/81 ,  C07D401/06 ,  C07D401/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/10 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides, in part, compounds of Formula I: N-oxides thereof, and pharmaceutically acceptable salts of the compounds or N-oxides; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M1-mediated (or M1-associated) disorders including, e.g., Alzheimer's disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Abstract translation: 本发明部分提供式I的化合物：其N-氧化物和化合物或N-氧化物的药学上可接受的盐; 制备过程; 中间体用于制备; 以及含有这些化合物，N-氧化物或盐的组合物及其用于治疗M1介导的（或M1相关）疾病的用途，包括例如阿尔茨海默病，精神分裂症（例如其认知和阴性症状），疼痛，成瘾， 和睡眠障碍。

公开(公告)号：US20190382359A1

公开(公告)日：2019-12-19

申请号：US16547037

申请日：2019-08-21

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D493/10 ,  C07D405/12 ,  C07D413/14 ,  C07D405/14 ,  C07F9/6561 ,  C07D515/10 ,  C07D471/08 ,  C07D211/48 ,  C07D487/04 ,  C07D471/10 ,  C07D401/12 ,  C07D491/107 ,  C07D498/10 ,  C07D403/04 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20170044174A1

公开(公告)日：2017-02-16

申请号：US15305384

申请日：2015-04-14

Applicant: PFIZER INC.

Inventor： DAVID LAWRENCE FIRMAN GRAY ,  LEI ZHANG ,  MICHAEL AARON BRODNEY ,  JENNIFER ELIZABETH DAVOREN ,  IVAN VIKTOROVICH EFREMOV ,  MICHAEL ERIC GREEN ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS

IPC: C07D491/048 ,  C07D403/12 ,  C07D491/052 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D491/048 ,  C07D403/12 ,  C07D471/04 ,  C07D487/04 ,  C07D491/052

Abstract: The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

Abstract translation: 本发明部分提供式（I）的化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 以及含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如其认知和阴性症状），分裂型人格障碍，认知障碍（例如认知障碍相关 精神分裂症，AD，PD或药物治疗），ADHD，帕金森病，焦虑和抑郁。

公开(公告)号：US20150307494A1

公开(公告)日：2015-10-29

申请号：US14694333

申请日：2015-04-23

Applicant: PFIZER INC.

Inventor： DAVID LAWRENCE FIRMAN GRAY ,  LEI ZHANG ,  MICHAEL AARON BRODNEY ,  MICHAEL ERIC GREEN ,  CHAKRAPANI SUBRAMANYAM

IPC: C07D471/04 ,  C07D401/12

CPC classification number: C07D403/12 ,  C07D401/12 ,  C07D471/04

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

Abstract translation: 本发明部分提供式I化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如其认知和阴性症状），分裂型人格障碍，认知障碍（例如，认知障碍相关 精神分裂症，AD，PD或药物治疗），ADHD，帕金森病，焦虑和抑郁。

公开(公告)号：US20150005313A1

公开(公告)日：2015-01-01

申请号：US14311963

申请日：2014-06-23

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  JENNIFER ELIZABETH DAVOREN ,  AMY BETH DOUNAY ,  IVAN VIKTOROVICH EFREMOV ,  DAVID LAWRENCE FIRMAN GRAY ,  MICHAEL ERIC GREEN ,  JACLYN LOUISE HENDERSON ,  CHEWAH LEE ,  SCOT RICHARD MENTE ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  LEI ZHANG

IPC: C07D401/14 ,  C07D401/12

CPC classification number: C07D401/14 ,  A61K31/444 ,  A61K31/501 ,  A61K31/506 ,  A61K31/513 ,  C07D401/12 ,  C07D403/12 ,  C07D405/14

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.

Abstract translation: 本发明部分提供式I化合物及其药学上可接受的盐; 制备过程; 中间体用于制备; 和含有这些化合物或盐的组合物及其用于治疗D1介导的（或D1相关）疾病的用途，包括例如精神分裂症（例如，其认知和负面症状），认知障碍（例如，与精神分裂症相关的认知障碍，AD ，PD或药物治疗），年龄相关的认知衰退，痴呆和帕金森病。